4579 Stock Overview
Engages in the research and development of pharmaceutical compounds worldwide.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
RaQualia Pharma Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | JP¥656.00 |
52 Week High | JP¥943.00 |
52 Week Low | JP¥525.00 |
Beta | 0.64 |
11 Month Change | 6.15% |
3 Month Change | 7.54% |
1 Year Change | -10.87% |
33 Year Change | -32.58% |
5 Year Change | -53.57% |
Change since IPO | -56.27% |
Recent News & Updates
Recent updates
With RaQualia Pharma Inc. (TSE:4579) It Looks Like You'll Get What You Pay For
Jul 17Companies Like RaQualia Pharma (TYO:4579) Can Afford To Invest In Growth
Apr 02The RaQualia Pharma (TYO:4579) Share Price Has Soared 410%, Delighting Many Shareholders
Feb 08Companies Like RaQualia Pharma (TYO:4579) Can Afford To Invest In Growth
Dec 17Shareholder Returns
4579 | JP Pharmaceuticals | JP Market | |
---|---|---|---|
7D | 10.6% | 0.2% | 0.3% |
1Y | -10.9% | 21.1% | 25.7% |
Return vs Industry: 4579 underperformed the JP Pharmaceuticals industry which returned 21.1% over the past year.
Return vs Market: 4579 underperformed the JP Market which returned 25.7% over the past year.
Price Volatility
4579 volatility | |
---|---|
4579 Average Weekly Movement | 4.6% |
Pharmaceuticals Industry Average Movement | 3.9% |
Market Average Movement | 3.8% |
10% most volatile stocks in JP Market | 7.3% |
10% least volatile stocks in JP Market | 1.9% |
Stable Share Price: 4579 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4579's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2008 | 67 | Hirobumi Takeuchi | www.raqualia.co.jp |
RaQualia Pharma Inc. engages in the research and development of pharmaceutical compounds worldwide. Its human products portfolio includes tegoprazan for gastroesophageal reflux disease, which is in phase 3 clinical trial in the United States; and grapiprant for cancer, which is in phase I clinical trial in China and the United States, as well as grapiprant for pain management The company also provides veterinary products, such as grapiprant for osteoarthritis in dogs; ghrelin receptor agonist to treat cancer-related anorexia/cachexia syndrome, and constipation resulting from spinal cord injury; and ELURA, a drug for the management of weight loss in cats with chronic kidney disease. In addition, it provides TRPM8 blocker for the indication of chronic pain; motilin receptor agonist to treat gastrointestinal dysmotility, including gastroparesis, functional dyspepsia, and post-operative ileus; 5-HT4 partial agonist to treat gastroparesis, functional dyspepsia, and chronic constipation; 5-HT2B antagonist to treat irritable bowel syndrome with diarrhea; EP4 antagonist, a pain management drugs for dogs; serotonin 5-HT2A and dopamine D2 receptor blocker to treat schizophrenia; EP4 antagonist to treat cancer that is in phase I clinical trial; Cyclooxygenase-2 inhibitor, which is in phase I clinical trials for the indication of pain; CB2 agonist for pain; selective sodium channel blocker for pain and itch; P2X7 receptor antagonist, which is in Phase 2 clinical trials for the target indication of chronic pain.
RaQualia Pharma Inc. Fundamentals Summary
4579 fundamental statistics | |
---|---|
Market cap | JP¥14.19b |
Earnings (TTM) | -JP¥253.00m |
Revenue (TTM) | JP¥2.18b |
6.5x
P/S Ratio-56.1x
P/E RatioIs 4579 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
4579 income statement (TTM) | |
---|---|
Revenue | JP¥2.18b |
Cost of Revenue | JP¥1.00m |
Gross Profit | JP¥2.18b |
Other Expenses | JP¥2.43b |
Earnings | -JP¥253.00m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 14, 2024
Earnings per share (EPS) | -11.69 |
Gross Margin | 99.95% |
Net Profit Margin | -11.61% |
Debt/Equity Ratio | 62.5% |
How did 4579 perform over the long term?
See historical performance and comparison